The Circulation Supplement Guide

The symptoms that bring people to this shelf are familiar: legs that feel heavy by the afternoon, ankles that mark when a sock comes off, a dull ache after a day standing still. In the clinical literature these sit under chronic venous disease, which is a spectrum running from tired legs at one end to skin changes and ulceration at the far one.

The mechanism review describes the underlying problem as a failure of the valves and the vessel wall to return blood upward against gravity. Pressure rises in the small vessels, fluid moves out into the tissue, and the inflammatory response that follows is what produces the ache and the swelling.

A venoactive drug — a phlebotonic — is a compound proposed to act on that chain: to raise the tone of the vein wall, to reduce how much fluid leaks from the capillaries, or to damp the inflammation once it has started. Several are prescription medicines in Europe. Most of what reaches a supplement shelf in the United States is a plant extract with the same proposed mechanism and a much weaker regulatory status.

That is the category. It is not a treatment for varicose veins, it does not reverse valve damage, and nothing in it is a substitute for being looked at if a leg has changed colour, broken down or swollen on one side only.

The 2020 Cochrane review of phlebotonics is the closest thing this field has to a settled answer. It pooled the randomised evidence across the whole class and concluded that phlebotonics probably reduce oedema slightly compared with placebo, with low-certainty evidence for several symptom measures and a modest increase in side effects.

Read that sentence carefully, because both halves matter. There is a measured effect on swelling, which is more than can be said for a great many supplement categories. It is described as slight, and the certainty attached to most of the symptom outcomes is low.

A 2024 update on herbal drugs in venous disease reaches a similar place from the plant end: a real pharmacology, a real but variable clinical record, and a persistent problem with how little two products carrying the same plant name have in common.

The honest summary is that this is a category where the best case is a modest improvement in swelling and comfort over three months, in people who also do the things in the last section of this guide. Anybody promising more than that is selling past the evidence.

Three tiers, and the tier a plant sits in is a statement about the published record rather than a judgement about the plant.

The first tier is where the category's reputation comes from. The Cochrane review of horse chestnut seed extract found improvements in leg pain, oedema and itching against placebo. The pooled analysis of butcher’s broom covered a combination product used across twenty trials. The gotu kola dose-ranging trial compared two daily amounts directly and found the larger one worked better, which is a rarer and more useful finding than another placebo comparison.

The second tier is the one that causes the most confusion on a shelf, because hawthorn has genuinely impressive trials attached to it and none of them measured a leg.

The third tier is not a criticism. A plant with no trial is a plant nobody has run a trial on, which is the ordinary condition of most of the botanical world. What it means is that a label carrying one has no dose to be compared against and no result to inherit.

The single most useful habit in this category is to read a milligram figure and then ask what it is a milligram of.

Every trial in the first tier used a standardised extract. Horse chestnut tablets standardised to a stated aescin content. Gotu kola standardised to its total triterpenic fraction. Hawthorn as WS 1442, a specific preparation with a specific procyanidin and flavonoid content. Grape seed as a proanthocyanidin extract at a stated concentration.

Standardisation is what makes the milligram mean something. Two hundred milligrams of a raw milled root and two hundred milligrams of an extract standardised to five per cent of an active constituent are the same weight of two very different things, and only one of them resembles what was tested.

A label that names a plant, states a weight and says nothing about standardisation has given you half a number. It is not necessarily a bad product; it is a product whose dose cannot be compared with the literature, which is a different problem and a permanent one.

On a liquid the gap widens. A tincture needs an extraction ratio before a volume can be converted into plant material at all, and a drop is not a unit of measurement: its size depends on the dropper bore, the viscosity and the temperature of the room.

Read off the trials themselves rather than from secondary summaries. The right-hand column is the one most often left out of a marketing claim.

Nothing in that table measured anything in the first week, and most of it measured nothing before week eight. That is the single most practical fact in this guide.

It follows that a supplement judged after seven days has not been judged. A first week tells you whether you can tolerate the taste, whether the routine sticks and whether anything disagrees with you, all of which are worth knowing and none of which is the question you bought it to answer.

It also follows that a pack size is a decision about evidence rather than about money. A single bottle that runs out at week four ends before the shortest trial window closes, which means it can only answer the tolerance question.

Those four are why individual results vary so widely in this category, and why a supplement started in spring is so often credited with a summer of walking more. A person who begins a bottle and also begins wearing compression stockings has changed two things at once and can attribute the result to either.

None of this makes a venoactive supplement pointless. It makes it the smaller of two levers, and a guide that did not say so would be worth less than the paper it is not printed on.

A dietary supplement in the United States may make a structure-and-function claim: a statement about an effect on the ordinary workings of the body. “Supports healthy circulation” is that kind of claim.

It may not make a disease claim. Naming a diagnosed condition — venous insufficiency, varicose veins, oedema as a diagnosis — turns the product into an unapproved drug, which is why label copy in this category is written in the careful register it is.

None of these claims is reviewed before the product goes on sale. The seller is responsible for substantiating it and the agency acts afterwards. That is why the required statement appears on every label and at the foot of every page on this website.

What this means for a reader is simple. The claim on the front of a bottle tells you what the seller decided to write. It is not a finding, it has not been assessed, and the useful information is further back, on the ingredient list and in whatever amounts are printed beside it.

Three limits, stated here rather than left for a reader to discover.

This guide covers oral plant extracts sold as supplements. It does not cover prescription venoactive drugs, sclerotherapy, ablation or surgery, all of which are real options with their own evidence and belong in a consultation rather than on a retail website.

It describes the category, not any particular bottle. Whether a specific product resembles the preparations in the trials depends on its extract, its standardisation and its dose, and most labels do not publish enough to tell.

And it is published by a desk that sells one of these products. That is disclosed on the about page and the defence against it is the citation list below: every claim in this guide links to a record you can open and read without taking this desk's word for anything.